-
MLN8237 (Alisertib): Reliable Aurora A Inhibition for Cancer
2026-05-16
This article demonstrates how MLN8237 (Alisertib) (SKU A4110) addresses reproducibility, selectivity, and workflow challenges in cell viability, apoptosis, and tumor inhibition assays. Drawing on peer-reviewed evidence and best-practice workflow guidance, it equips biomedical researchers and lab technicians with scenario-driven insights for robust experimental design.
-
Myriocin: Precision Serine Palmitoyltransferase Inhibitor Wo
2026-05-15
Myriocin enables targeted, reproducible inhibition of sphingolipid biosynthesis, empowering advanced workflows in cancer, metabolic, and cardiovascular research. Explore real-world experimental setups, protocol optimizations, and troubleshooting strategies to maximize assay reliability with APExBIO's high-purity Myriocin.
-
Reelin–Src Pathway Is Essential for Ketamine’s Antidepressan
2026-05-15
This study demonstrates that intact Reelin-Apoer2-Src family kinase (SFK) signaling is required for ketamine-induced synaptic plasticity and behavioral changes in mouse models. The findings offer mechanistic insight into why some patients with treatment-resistant depression do not respond to ketamine, highlighting the importance of baseline NMDA receptor function maintained by Reelin signaling.
-
Y-27632 Dihydrochloride: ROCK Inhibitor Workflows in Stem Ce
2026-05-14
Y-27632 dihydrochloride, a selective ROCK inhibitor from APExBIO, drives reproducible gains in stem cell viability and robust suppression of tumor invasion. This guide delivers actionable protocols, troubleshooting strategies, and key insights from recent iPSC disease modeling breakthroughs.
-
Y-27632 Dihydrochloride: Targeting ROCK1/2 in Barrier and Vi
2026-05-14
Explore how Y-27632 dihydrochloride, a potent ROCK inhibitor, advances research in cytoskeletal dynamics, barrier function, and viral entry. This article uniquely connects molecular mechanism to practical assay design with new evidence from cell junction and infection models.
-
Refining In Vitro Metrics for Evaluating Anti-Cancer Agents
2026-05-13
Schwartz’s dissertation establishes a rigorous framework for differentiating between proliferative arrest and cell death in in vitro anti-cancer drug assays. This method enhances mechanistic understanding of drug responses, improving the translational value of preclinical cancer research.
-
5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole: Precision Tra
2026-05-13
Unlock targeted transcriptional regulation and advanced assay reproducibility with 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB). This guide delivers actionable workflows, troubleshooting insights, and evidence-based applications for DRB in cell biology, virology, and translational research.
-
IRF1-PARP12 Axis Impairs Mitophagy and Drives Cartilage Degr
2026-05-12
This study uncovers how IRF1-driven upregulation of PARP12 impairs PINK1/Parkin-dependent mitophagy in chondrocytes, promoting cartilage degradation in osteoarthritis. The work highlights the mechanistic link between inflammatory signaling, mitochondrial quality control, and cartilage pathology, and demonstrates that XAV-939 can suppress PARP12 and OA progression in both cell and animal models.
-
Radiotherapy Plus PD-1/TIGIT Blockade: CD8+ T Cells Drive Ab
2026-05-12
This study demonstrates that combining radiotherapy with dual PD-1 and TIGIT immune checkpoint blockade generates robust antitumor abscopal effects and durable immune memory through CD8+ T cell activation. The findings clarify the cellular mechanisms behind enhanced tumor control and inform strategies to overcome resistance seen with immunotherapy alone.
-
XAV-939 in Applied Wnt/β-Catenin Research: Protocols & Pitfa
2026-05-11
XAV-939 (NVP-XAV939) stands out for precise, reproducible modulation of the Wnt/β-catenin pathway in cancer, fibrosis, and osteogenic differentiation research. Explore advanced workflows, real-world troubleshooting, and key insights from recent literature to maximize data quality and biological relevance.
-
Temafloxacin: Fluoroquinolone Broad-Spectrum Antibacterial A
2026-05-11
Temafloxacin empowers researchers with flexible, high-precision antibacterial workflows for both standard and intracellular infection models. Its well-characterized activity spectrum and robust pharmacology support advanced applications, particularly in studies of Gram-positive, Gram-negative, and atypical pathogens, including Mycobacterium avium complex.
-
Salinomycin: Polyether Ionophore Antibiotic in HCC Assays
2026-05-10
Salinomycin’s dual action as an ABC transporter and Wnt/β-catenin pathway inhibitor makes it a cornerstone for advanced hepatocellular carcinoma research. Explore how optimized protocols and troubleshooting insights with APExBIO’s Salinomycin enable high-precision apoptosis and proliferation assays, validated by cutting-edge systems biology approaches.
-
Palbociclib (PD0332991): Precision CDK4/6 Inhibition in Canc
2026-05-09
Unlock the full experimental potential of Palbociclib (PD0332991) in advanced cancer research, from robust G0/G1 cell-cycle arrest assays to cutting-edge assembloid applications. Discover workflow refinements and troubleshooting strategies that elevate reproducibility and translational value in breast cancer and RCC studies.
-
Aurora A Kinase Regulates Trained Immunity via SAM Metabolis
2026-05-08
This study reveals Aurora kinase A (AurA) as a central regulator of trained immunity in innate immune cells through control of S-adenosylmethionine (SAM) metabolism. By connecting AurA activity to chromatin accessibility and epigenetic programming, the findings offer new insight into oncogenesis, cancer biology, and the immunometabolic axes relevant for tumor progression and therapeutic intervention.
-
Plk1-Dependent Regulation of p31comet in Mitotic Checkpoint
2026-05-08
This study elucidates how Polo-like kinase 1 (Plk1) regulates p31comet-mediated disassembly of mitotic checkpoint complexes, a critical process for accurate chromosome segregation. By demonstrating Plk1's phosphorylation of p31comet on S102 and subsequent modulation of spindle assembly checkpoint resolution, the work clarifies a longstanding gap in our understanding of checkpoint inactivation and highlights new avenues for precision cell cycle research.